microRNAs deregulation in head and neck squamous cell carcinoma

Abstract

Head and neck (HN) squamous cell carcinoma (SCC) is the eighth most common human cancer worldwide. Besides tobacco and alcohol consumption, genetic and epigenetic alterations play an important role in HNSCC occurrence and progression. microRNAs (miRNAs) are small noncoding RNAs that regulate cell cycle, proliferation, development, differentiation, and apoptosis by interfering in gene expression. Expression profiling of miRNAs showed that some miRNAs are upregulated or downregulated in tumor cells when compared with the normal cells. The present review focuses on the role of miRNAs deregulations in HNSCC, enrolled in risk, development, outcome, and therapy sensitivity. Moreover, the influence of single nucleotide variants in miRNAs target sites, miRNAs seed sites, and miRNAs-processing genes in HNSCC was also revised. Due to its potential for cancer diagnosis, progression, and as a therapeutic target, miRNAs may bring new perspectives in HNSCC understanding and therapy, especially for those patients with no or insufficient treatment options.

Identification of Tumor-Suppressive miR-30e-3p Targets: Involvement of SERPINE1 in the Molecular Pathogenesis of Head and Neck Squamous Cell Carcinoma

“…A single miRNA might control a great number of RNA transcripts and contribute to various cellular signaling pathways under both normal and pathological conditions [ 10 , 12 ]. A vast number of studies have shown that aberrantly expressed miRNAs can function as oncogenes and/or tumor suppressors in human cancer cells, including HNSCC [ 13 , 14 ].…”

Does the Necrotic Portion of Metastatic Lymphadenopathy from Squamous Cell Carcinoma Still Have Tumoral Oncologic Information? Differential Diagnosis of Benign Necrotic Lymphadenopathy Using microRNA

“…The role of miRNAs was usually defined as oncogenes and suppressor genes in HNSCC. A recent study reviewed upregulated and downregulated miRNAs in HNSCC [ 32 ] and showed multiple well-studied miRNAs in HNSCC. Among them, hsa-miR-1, hsa-miR-31, hsa-miR-141, hsa-miR-146, hsa-miR-155, hsa-miR-200, hsa-miR-203, and hsa-miR-205 were commonly downregulated in the tumor necrosis group compared to those in the benign inflammatory necrosis group.…”

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)

“…There have been significant advancements in surgery, radiotherapeutics, chemotherapy and immunotherapy as treatment approaches. In radiotherapy, the development of different fractionating schemes and intensity-modulated radiotherapy has enhanced the delivery and tolerance of radiation ( 32 ). Organ function conservation is improved through the advancement in conservative surgical procedures, including laryngeal prosthesis, laser surgery and hemilaryngectomy ( 33 ).…”